What are therapeutic equivalents to 2.5 mg of letrozole (Arimidex)?

Therapeutic Equivalents to Letrozole 2.5 mg

Yes, anastrozole (Arimidex) 1 mg daily is the therapeutic equivalent to letrozole 2.5 mg daily for breast cancer treatment. Both are third-generation nonsteroidal aromatase inhibitors with comparable efficacy and safety profiles in hormone receptor-positive breast cancer.

Direct Equivalence

The FDA-approved dose of anastrozole is 1 mg once daily 1, which achieves similar aromatase inhibition and estrogen suppression as letrozole 2.5 mg daily. Both drugs:

• Suppress serum estradiol by approximately 70-80% 1
• Reduce estradiol to the lower limit of detection (3.7 pmol/L)
• Achieve steady-state levels within 7 days of daily dosing
• Are selective nonsteroidal aromatase inhibitors with no effect on corticosteroid synthesis

Clinical Evidence Supporting Equivalence

In the adjuvant breast cancer setting, multiple ASCO guideline-referenced trials demonstrate interchangeable use:

• The DATA trial directly compared anastrozole 1 mg daily for 6 years versus 3 years after tamoxifen, showing efficacy comparable to letrozole trials 2
• The MA.17R and NSABP B-42 trials used letrozole 2.5 mg daily with similar disease-free survival outcomes 2
• Both agents showed equivalent adverse event profiles including arthralgia (53-58%), bone fractures (5-14%), and cardiovascular events (1.5-4%) 2

In metastatic breast cancer, the MONALEESA-2 trial combined letrozole 2.5 mg with ribociclib, while other trials have successfully used anastrozole in identical settings, confirming therapeutic equivalence 3.

Important Clinical Considerations

Dosing Specifics

• Anastrozole (Arimidex): 1 mg once daily - this is the only FDA-approved dose
• Letrozole: 2.5 mg once daily - standard dose
• Do not attempt dose conversions or adjustments between these agents; use the established therapeutic doses

Side Effect Profile

Both agents share similar toxicity patterns 2:

• Musculoskeletal symptoms (arthralgia, myalgia): 50-69%
• Bone health concerns: increased fracture risk (NNH = 72)
• Cardiovascular events: slight increase (NNH = 122)
• Hot flashes: 37-54%
• No difference in quality of life measures between agents

When NOT to Substitute

• Premenopausal women: Neither agent is effective as aromatization of adrenal androgens is not the primary estrogen source 1
• Severe hepatic impairment: Anastrozole has not been studied in this population 1
• Active treatment protocols: If a patient is enrolled in a clinical trial or specific protocol, maintain the prescribed agent

Practical Switching Algorithm

You can directly switch between these agents 1:1 without washout period:

1. From letrozole 2.5 mg to anastrozole 1 mg: Simply substitute the next scheduled dose
2. From anastrozole 1 mg to letrozole 2.5 mg: Simply substitute the next scheduled dose
3. No dose titration needed: Both achieve maximal estrogen suppression at standard doses
4. Monitor for tolerability: While efficacy is equivalent, individual patients may tolerate one agent better than the other

Common Pitfall to Avoid

Do not use lower or intermittent doses thinking they are equivalent. While research shows that letrozole 2.5 mg three times weekly achieves 75-78% estrogen suppression 4, this is not FDA-approved and should not be considered therapeutically equivalent to standard daily dosing for breast cancer treatment.

Bottom line: Anastrozole 1 mg daily and letrozole 2.5 mg daily are therapeutically equivalent and interchangeable for hormone receptor-positive breast cancer treatment in postmenopausal women.